• Downloads
  • Contact Us
  • Directions
  • Deutsch Deutsch German de
  • English English English en
  • 简体中文 简体中文 Chinese (Simplified) zh-hans
Epitype GmbH
  • Products
  • About us
    • Management
    • Team
    • Research projects
    • Publications
    • Press
    • Jobs
  • Contact
    • Directions
    • Contact Us
  • News / Blog
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%

Press Releases
Ärztin schaut durch ein Kolposkop. Symbolbild für die Pressemeldung der oncgnostics GmbH: Methylierungstests beim Gebärmutterhalskrebs-Screening könnten invasive Verfahren um bis zu 75 % reduzieren.Peakstock / Shutterstock

Porto / Jena, November 26, 2024 – Methylation tests could significantly increase the accuracy of cervical cancer screening and reduce referrals for colposcopy, which would, in turn, put less strain on the healthcare system. A recent study published in the “Journal of Lower Genital Tract Disease” found that methylation testing of cervical cancer cells could serve as a highly effective method for women who test positive for high-risk Human Papillomavirus (hrHPV).

Fewer colposcopies thanks to methylation tests

The study, titled “Evaluation of Host Gene Methylation as a Triage Method for HPV-Positive Women,” focused on the use of methylation biomarkers to improve the management of HPV-positive cases. Methylation is an epigenetic modification that has been closely associated with cancer development.

All 278 women included in this study were referred due to a positive hrHPV test. Seventy-one of these women tested positive for methylation (25.5%). These results indicate that if methylation testing was used for all hrHPV-positive women, and only methylation-positive women would be referred to colposcopy, there could be a 74.5% drop in referrals at a cost of not diagnosing 22% of high-grade lesions. If methylation testing would be used on women who tested positive for hrHPV genotypes other than 16 or 18, overall referral rate would drop by 60%, at a cost of not diagnosing 10% of high-grade lesions. The option of sending women who test HPV16 or HPV18 positive directly to colposcopy and applying further triage to the ones who tested positive for other HPV genotypes is in line with most cervical cancer screening guidelines.

Impact on the healthcare system

“The HPV test revolutionized cervical cancer screening. The next major advancement will be effectively triaging those who test positive, thereby reducing both the number of colposcopies and overtreatments. This paper enhances existing data on the role of methylation tests and supports their potential as a frontline tool in achieving this goal,” says Dr. Pedro Vieira Baptista, President-Elect of the International Society for the Study of Vulvovaginal Disease and the head of this study.

Dr. Alfred Hansel, Managing Director of oncgnostics GmbH, whose GynTect methylation test was used for the study, adds, “If methylation tests were included in a regulated cervical cancer screening program, up to three quarters of colposcopy procedures could be avoided. This would not only benefit affected women, who would receive a quick and reliable diagnosis, but would also significantly lower the burden on the healthcare system.”

Implications for cervical cancer screening

Most cases of cervical cancer are caused by a long-lasting infection with hrHPV. Traditional screening methods include a Pap smear and/or an HPV test, both of which involve taking a smear of the cervix by a health care professional and sending it to a laboratory.While Pap smears and HPV tests are effective, less than one-third of severe cancer lesions progress to invasive cancer, meaning that a high number of women undergo needless stress and invasive testing.

If women receive a positive HPV test or suspicious Pap smear, they will likely be referred for a procedure called a colposcopy. Here, a light microscope (colposcope), is used to examine the cervix, vagina and vulva. When an abnormality is discovered, a biopsy may be taken for further evaluation. This entire procedure requires allotted time, specific equipment and experienced personnel. This translates into strain on the healthcare system and significant patient anxiety.

Methylation assays in cervical cancer screening

In recent years, hrHPV tests have become a cornerstone for screening cervical cancer and its precursors. Much of this is attributed to less invasiveness, higher sensitivity and fewer false-negatives compared to current routine standards of care.

The methylation assay used in this study targets methylation in six gene regions. These regions have been shown to strongly correlate with high grade intraepithelial neoplasia (HSIL) and cervical cancer. In fact, the study found that this methylation test has a high sensitivity and specificity for HSIL and cancer. Therefore, taking all results into account, hrHPV tests in combination with methylation testing could serve as a reliable cervical cancer screening method to distinguish between women who require immediate clinical assistance and those who can be safely monitored, thereby reducing invasive procedures.

Oncgnostics GmbH

oncgnostics GmbH, founded in 2012 as a spin-off from the University Women’s Hospital in Jena, specializes in the development of diagnostic tests based on epigenetic markers, specifically DNA methylation. The first CE IVD tests for cervical cancer, GynTect and ScreenYu Gyn, were introduced to the market by oncgnostics. oncgnostics leverages its expertise and technological platforms to develop further diagnostic tests, currently focused on head and neck tumors.

+++

Reference:

Vieira-Baptista, P., Costa, M., Hippe, J., Sousa, C., Schmitz, M., Silva, A.-R., Hansel, A., & Preti, M. (2024). Evaluation of host gene methylation as a triage test for HPV–positive women—a cohort study. Journal of Lower Genital Tract Disease.

26. November 2024/by Admin Spinger
Share this entry
  • Share on WhatsApp
https://www.epitype.de/wp-content/uploads/2024/11/PM-Titel-Studie-1.png 321 845 Admin Spinger https://www.epitype.de/wp-content/uploads/2025/09/epitype_website-logo-300x130.png Admin Spinger2024-11-26 12:49:152024-11-26 12:55:53Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%

Archive

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Epitype GmbH

The Epitype GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.

Epitype GmbH is working according to ISO 13485 standards in research, development, production and management.

Recent Posts

  • Worldwide unique test for cervical cancer as a gamechanger for the healthcare system
  • Jena Biotechnology Company Files for Insolvency
  • Bachelor thesis in biotechnology companies: From research to diagnostics 

Contact

Epitype GmbH
Löbstedter Str. 41
07749 Jena
Germany

Phone: +49 (0)3641 5548500

Email: contact[at]epitype.de
Internet: www.epitype.de

© 2015 - 2025 Epitype GmbH Jena Germany
  • Start
  • Imprint
  • Contact Us
  • Privacy policy
Scroll to top

Cookies help us deliver our services. By using our services, you agree to our use of cookies.

Learn moreI accept

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy policy
Einstellungen akzeptierenVerberge nur die Benachrichtigung
Epitype GmbH
Manage Consent

To provide you with the best possible experience, we use technologies such as cookies to store and/or access device information. If you consent to these technologies, we may process data such as browsing behavior or unique identifiers on this website. If you do not give your consent or withdraw it, certain features and functions may be affected.

Functional Always active
Technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service expressly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a message via an electronic communications network.
Preferences
Technical storage or access is necessary for the legitimate purpose of storing preferences that have not been requested by the subscriber or user.
Statistics
Technical storage or access carried out solely for statistical purposes. Technical storage or access used exclusively for anonymous statistical purposes. Without a court order, the voluntary consent of your internet service provider or additional records from third parties, the information stored or accessed for this purpose cannot, as a rule, be used on its own to identify you.
Marketing
Technical storage or access is required to create user profiles, to send advertising, or to track the user on a website or across multiple websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View settings
  • {title}
  • {title}
  • {title}